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Abstract
Background: Interpretation of the complete blood count 
(CBC) parameters requires reliable biological variation 
(BV) data. The aims of this study were to appraise the 
quality of publications reporting BV data for CBC para-
meters by applying the BV Data Critical Appraisal Check-
list (BIVAC) and to deliver global BV estimates based on 
BIVAC compliant studies.
Methods: Relevant publications were identified by a sys-
tematic literature search and evaluated for their compliance 
with the 14 BIVAC criteria, scored as A, B, C or D, indicating 
decreasing compliance. Global CVI and CVG estimates with 
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95% CI were delivered by a meta- analysis approach using 
data from BIVAC compliant papers (grades A–C).
Results: In total, 32 studies were identified; four received 
a BIVAC grade A, 2 B, 20 C and 6 D. Meta-analysis derived 
CVI and CVG estimates were generally lower or in line with 
those published in a historical BV database available 
online. Except for reticulocytes, CVI estimates of erythro-
cyte related parameters were below 3%, whereas platelet 
(except MPV and PDW) and leukocyte related parameters 
ranged from 5% to 15%.
Conclusions: A systematic review of CBC parameters has 
provided updated, global estimates of CVI and CVG that will 
be included in the newly published European Federation of 
Clinical Chemistry and Laboratory Medicine BV Database.
Keywords: biological variation; erythrocyte; haemoglo-
bin; leukocyte; meta-analysis; platelets.
Introduction
The complete blood count (CBC) is one of the most com-
monly ordered blood tests in clinical practice. Defining 
analytical performance specifications (APSs) for each CBC 
component is essential to ensure that the measurement 
error will not distort the clinical interpretation of the result 
[1–4]. According to the consensus statement delivered by 
the 1st Strategic Conference of the European Federation of 
Clinical Chemistry and Laboratory Medicine (EFLM), the 
recommended approaches for deriving APS should pref-
erably rely on (1) the effect of measurement performance 
on clinical outcome (model 1) or on (2) the biological 
variation (BV) of the measurand (model 2) [5, 6]. If APS 
based on these models cannot be made, state-of-the-art, 
defined as the highest level of performance technically 
achievable, could be used (model 3). However, it is gen-
erally agreed that analytical quality should be compared 
against objective APSs, considering that models 1 or 2 are 
preferred [7, 8]. On the basis of a preliminary list prepared 
by the EFLM Task and Finish Group on Allocation of Labo-
ratory Tests to Different Models for Performance Specifica-
tions (TFG-DM), most CBC components are assigned to the 
BV model [9].
The availability of BV data also allows the derivation 
of other parameters, such as (i) the index of individual-
ity (II) the evaluation of the utility of population refer-
ence intervals, (ii) the reference change value (RCV), i.e. 
the estimate of a significant change in a timed series of 
results of an individual and (iii) the number of specimens 
required to obtain an accurate estimate of the homeostatic 
set point of the analyte [3, 10, 11].
Since the 1970s, many papers on BV of CBC para-
meters have been published. The medians of the BV esti-
mates delivered by most of these publications have for the 
last decades been available in the historical BV database 
(HBVD), which was updated every 2 years until 2014 [12, 
13]. However, concerns about the quality and validity of 
these data have been raised [14, 15]. In response to this, the 
EFLM BV Working Group (EFLM BV-WG) and Task Group 
on the BV Database have developed the BV Data Critical 
Appraisal Checklist (BIVAC) [16], which is designed to 
assess the quality of BV publications by verifying whether 
all essential elements that may impact upon veracity and 
utility of the associated BV estimates are present. Further-
more, a meta-analysis approach to deliver global estimates 
based on BIVAC compliant studies has been constructed. 
For CBC parameters, obtaining reliable BV estimates is 
particularly challenging. Due to stability issues, blood 
samples cannot be stored and, consequently, the meas-
urement of all samples from the same person cannot be 
performed in a single centre in a single analytical run on 
the same day, which is the usual recommended approach. 
Generally, to obtain reliable BV data of CBC parameters, 
the protocol and the checklist developed by EFLM BV-WG 
[17, 18] should be followed, as in two recently published 
national studies [19–22].
The aims of the present study were to systematically 
appraise published BV data of CBC parameters by use of 
the BIVAC [16] and to extract BV data from BIVAC-compli-
ant studies to deliver global BV estimates for CBC para-
meters by meta-analysis.
Materials and methods
Bibliographic research
Firstly, the references in the HBVD [12] related to the BV 
of CBC parameters were considered. This retrieved 18 
papers, all of which were published before 2014. There-
after, a systematic bibliographic research was performed 
in Web of Science and PubMed in November 2018, apply-
ing the terms “biological variation”, “biological variabil-
ity”, “CBC”, “haematology”, with limits ‘‘Title/Abstract, 
Human Subjects, English”. An additional 14 papers were 
identified by this approach, giving in total 32 papers that 
were included in the study. Studies published prior to 2014 
are identified by the numbers they have had assigned in 
the HBVD. The same numbering system is used in the 
EFLM Biological Variation Database [23] for papers pub-
lished after 2014 (Supplementary Table 1).
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Appraisal of publications by the BIVAC
All 32 papers were evaluated by two reviewers indepen-
dently for their compliance with the 14 BIVAC quality 
items (QIs), which may receive scores A, B, C and/or D 
[16]. In the BIVAC, an overall grade A indicates full com-
pliance with all QIs; a grade B is given if the lowest QI 
score achieved is a B, and similarly grade C, if the lowest 
QI score is C. Studies are graded D if they lack essential 
BIVAC elements (QI 2–4). A subscript system is applied to 
illustrate the scores. For example, if a paper was classified 
as “C” due to the items 2,5,6,7, the grade of the paper is 
given as “C2,5,6,7”.
The method used to evaluate the BV studies has 
recently been described in detail by Díaz-Garzón [24] and 
González-Lao et  al. [25]. When estimates from different 
populations or sampling intervals were included for the 
same measurand, BIVAC assessment and data extraction 
were performed for each subgroup/sampling interval. In 
addition, data for 30 descriptive items such as study dura-
tion, subjects’ health status, sample types, sampling time 
and interval, analytical methods, number of samples, etc. 
were extracted from each paper. Confidence intervals (CIs) 
at 95% for both CVI and CVG were calculated as described 
by Burdick and Graybill [26].
Meta-analysis
For each CBC parameter, global CVI and CVG were esti-
mated by a meta-analysis approach using data extracted 
from BIVAC-compliant [16] papers, i.e. those receiving an 
overall BIVAC grade A, B or C. Papers classified as D and 
studies/study subgroups that did not fulfill the following 
inclusion criteria were excluded: (i) healthy individuals, 
(ii) subject age (min–max; 18–75 years) and (iii) estimates 
for within day variation [24].
Furthermore, studies/study subgroups were excluded 
from the meta-analysis if the following criteria were 
fulfilled:
 – the CVI and CVG estimates were reported as 0; as was 
the case for platelets in paper 28
 – results for more than one CBC component were 
reported as one parameter; monocyte, basophils and 
eosinophils as in paper 36
 – more than one sample was collected from the same 
subjects at the same sampling time; paper 154
 – CVI and CVG estimates were derived from only two 
samples per subjects; paper 291
 – capillary samples; Hb and Hct from paper 9.
To calculate the weight of each estimate in the meta-anal-
ysis, the quality grade “A”, “B” and “C” were given a factor 
of 4, 2 and 1, respectively, and multiplied with the inverse 
width of their CI [16, 25]. Estimates from subgroups (e.g. 
male and female) from the same study were combined 
prior to being included in the meta-analysis. Finally, a 
percentile boot strap technique was used to calculate the 
CI of the global estimate [25, 27].
Results
Table 1 shows the number of papers, their BIVAC grade 
and the number of subgroups (different study popula-
tions, sampling intervals, etc.) included in our review. 
The number of publications per analyte is variable. For 
well-established parameters such as erythrocytes, Hb, 
leukocytes and platelets a number of papers ranging 
from a minimum of 12 for erythrocyte and leukocyte and a 
Table 1: Number of papers (N), number of study subgroups (n) and 
the BIVAC grade for publications reporting BV estimates for CBC 
parameters.
CBC parameters   N  n 
 
BIVAC grade
A  B  C  Da
Erythrocyte   12  33  2  1  9  4
Haemoglobin   21  60  2  1  18  6
Haematocrit   16  43  2  1  13  3
MCV   12  29  2  1  9  4
MCH   11  26  2  1  8  3
MCHC   11  28  2  1  8  4
RDW   4  8  2  0  2  1
Reticulocyte   5  10  2  1  2  0
Reticulocyte – He   2  6  2  0  0  0
Leukocyte   12  33  2  1  9  4
Lymphocyte   10  25  2  1  7  3
Monocyte   8  23  2  0  6  3
Neutrophil   9  25  2  1  6  3
Eosinophil   7  22  2  0  5  3
Basophils   7  21  2  0  5  3
Platelet   13  32  2  1  10  3
Plateletcrit   5  8  2  0  3  0
MPV   7  10  2  0  5  3
PDW   3  5  2  0  1  0
P-LCR   2  4  2  0  0  0
MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular 
haemoglobin concentration; MCV, mean corpuscular volume; RDW, 
red cell distribution wide; MPV, mean platelet volume; PDW, platelet 
distribution wide; P-LCR, platelet larger cell ratio; N, number of 
publications used to estimate the BV of CBC parameters; n, number of 
subgroups; aD papers and their subgroups were not included in N and n.
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maximum of 21 for Hb were identified, whereas for reticu-
locyte haemoglobin equivalent (Ret-He) and platelet larger 
cell ratio (P-LCR) only two papers were identified.
The different publications were assigned the follow-
ing BIVAC grades: A, n = 4; B, n = 2; and C, n = 20 (Supple-
mentary Table  1). QIs related to the statistical approach 
such as inadequate outlier analysis and/or lack of variance 
homogeneity testing were the most frequent cause (19/26; 
73%) of the BIVAC C grade classification (Table 1). In addi-
tion, six publications were classified as D, mainly due to 
sampling problems such as irregular timing of sample 
collections (BIVAC QI-3) [16]. The study designs described 
in the 26 eligible papers showed marked heterogeneity, 
reporting BV results for different subgroups of subjects, 
such as sex, age (adults (between 18 and 75 years), elderly 
(>75  years), sampling intervals (hourly, daily, weekly, 
monthly). We critically appraised data and assigned a 
BIVAC grade for each of these subgroups, obtaining in 
total 73 subgroup data sets (Supplementary Table 1), but 
except for two papers (papers 36 and 291) there was no 
difference between the BIVAC grade assigned to differ-
ent subgroup data sets derived from the same study. 
The meta-analysis derived results from our study were 
generally in line with or lower than those presented in the 
HBVD (Table 2). Estimates of CVI and CVG with 95% CI for 
the CBC parameters from all reviewed studies are shown 
in Figure  1 (erythrocytes, leukocytes and platelets) and 
Supplementary Figures 1–37, and the reasons for exclusion 
from meta-analysis are detailed. Supplementary Table  2 
shows the scoring system in detail for erythrocytes.
Discussion
To the best of our knowledge, this is the first study to 
perform a systematic review of the literature of BV of CBC 
parameters and to critically appraise these papers. The 
majority of the reviewed publications obtained a BIVAC 
C or D grade (Table 1). To obtain reliable estimates of BV 
from meta-analysis, it is important that included data are 
derived from studies with similar study populations and 
study designs. Therefore, in addition to BIVAC criteria, we 
applied additional exclusion criteria which caused five 
publications to be excluded from the meta-analysis.
Except for reticulocytes, CVI estimates of erythro-
cyte related parameters were below 3%, whereas platelet 
Table 2: Meta-analysis derived within-subject (CVI) and between-subject (CVG) BV estimates with 95% CIs of CBC parameters and estimates 
from the HBVD.
Measurands  
 
Meta-analysis-based estimates 
 
HBVD
NI  nI  Mean ± SD  CVI (CI), %  NG  nG  Mean ± SD  CVG (CI), % CVI, %  CVG, %
Erythrocyte, ×1012/L   7  12  4.82 ± 0.33  2.80 (1.96–3.07)  5  10  4.85 ± 0.36  6.29 (6.16–7.40)  3.20   6.30
Haemoglobin, mmol/L  11  21  8.77 ± 0.61  2.71 (1.72–2.80)  6  13  8.72 ± 0.63  6.07 (3.20–6.28)  2.85   6.80
Haematocrit, L/L   6  13  0.43 ± 0.03  2.71 (2.24–3.40)  6  13  0.43 ± 0.03  5.45 (3.40–5.51)  2.70   6.41
MCV, fL   7  12  88.4 ± 2.37  0.75 (0.64–1.17)  6  11  88.0 ± 2.10  3.78 (3.40–4.68)  1.40   4.85
MCH, fmol   6  9  1.85 ± 0.05  0.85 (0.24–1.60)  5  8  1.84 ± 0.05  4.30 (4.06–5.31)  1.40   5.20
MCHC, mmol/L   6  11  20.8 ± 0.38  0.95 (0.60–1.10)  5  10  20.9 ± 0.38  1.49 (1.25–2.30)  1.06   1.20
RDW, fL   3  7  40.9 ± 1.36  1.51 (1.08–1.90)  2  6  40.5 ± 0.96  4.75 (3.67–7.26)  3.5   5.70
Reticulocyte, ×1012/L   3  8  0.056 ± 0.009  9.74 (6.44–11.0)  3  8  0.056 ± 0.009  27.11 (22.13–30.53)  11   29
Reticulocyte – He, pg   2  6  33.4 ± 0.59  1.92 (0.75–3.40)  2  6  33.4 ± 0.59  3.38 (2.72–4.11)  NA   NA
Leukocyte, ×109   7  12  6.62 ± 0.39  10.01 (8.90–11.35)  4  7  6.75 ± 0.47  16.48 (15.78–23.70)  11.40   21.30
Lymphocyte, ×109   5  7  2.12 ± 0.08  10.13 (9.45–13.59)  4  6  2.12 ± 0.09  23.87 (21.30–25.10)  10.20   35.30
Monocyte, ×109   3  5  0.49 ± 0.11  12.85 (11.79–16.40)  2  4  0.54 ± 0.04  18.30 (15.86–22.26)  17.80   49.8
Neutrophil, ×109   5  8  3.81 ± 0.36  13.61 (6.30–20.37)  3  5  3.79 ± 0.48  21.16 (20.70–32.60)  17.10   32.80
Eosinophils, ×109   3  5  0.11 ± 0.06  14.38 (12.52–20.8)  2  4  0.13 ± 0.02  64.25 (59.89–70.50)  21.0   76.4
Basophils, ×109   3  4  0.05 ± 0.01  11.34 (11.21–32.0)  2  3  0.04 ± 0.002  25.07 (22.1–29.9)  28.0   54.8
Platelet, ×109   6  10  232.2 ± 15.6  7.1 (4.49–7.69)  5  8  232.3 ± 19.1  16.17 (10.80–22.36)  9.10   21.90
Plateletcrit, %   3  5  0.25 ± 0.02  5.94 (4.97–11.6)  2  4  0.26 ± 0.01  13.33 (12.49–14.08)  11.90   NA
MPV, fL   4  6  10.2 ± 0.84  2.02 (1.55–4.30)  2  4  10.6 ± 0.33  6.96 (6.96–8.10)  4.30   8.10
PDW, fL   2  4  12.61 ± 0.65  3.43 (3.10–3.69)  2  4  12.61 ± 0.65  12.31 (11.95–12.79)  2.80   NA
P-LCR, %   2  4  29.7 ± 2.60  5.70 (4.78–6.60)  2  4  29.7 ± 2.60  20.42 (19.79–21.27)  NA   NA
HBVD, Historical Biological Variation Database; CI, confidence intervals; NI, number of papers used in meta-analysis of CVI; NG, number of 
papers used in meta-analysis of CVG; nI, number of subgroups used in meta-analysis of CVI; nG, number of subgroups used in meta-analysis 
of CVG; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; MCV, mean corpuscular volume; RDW, 
red cell distribution wide; MPV, mean platelet volume; PDW, platelet distribution wide; P-LCR, platelet larger cell ratio.
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Figure 1: The CVI estimates with 95% confidence intervals for (A) erythrocytes, (B) leukocytes and (C) platelets.
The boxes indicate which studies were included in the meta-analysis, as well as the BIVAC grades awarded to the different studies. Reasons 
for exclusion from the meta-analysis are also shown. The different papers are identified on the x-axis with the letters indicating different 
study subgroups (see Supplementary Table 1).
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(except MPV and PDW) and leukocyte related parameters 
ranged from 5% to 15% (Table 2). The CVI estimates 
derived for MCV, MCH and MCHC were extremely low and 
with current technologies it is not easy to use and adopt 
APSs based on these results if the APSs are set at the desir-
able level, which is the most common approach. It may 
therefore be necessary to consider alternative approaches 
such as minimum level [3, 10], outcome studies (model 1) 
or state of the art (model 3) [6] to set APSs.
The HBVD has presented as the estimates of medians 
of data from publications published until 2014 [12]. There 
are no measures of uncertainty included in this overview 
and thus, direct statistical comparison with the results of 
our study is therefore not possible. We, however, evalu-
ated whether the CVI and CVG estimates included in the 
HBVD were within the limits of CIs for the estimates 
obtained from meta-analysis; this was the case for the CVI 
of eight out of 18 analytes and the CVG of seven out of 16 
analytes (Table 2). For the remainder, the point estimates 
for both CVI (except PDW) and CVG (except MCHC) in the 
HBVD were higher than the upper limits of CIs calculated 
from meta-analysis. It is worth noting that a number of 
the same studies makes up the basis for both the esti-
mates presented in the HBVD as well as in our study. The 
lower CVI and CVG estimates derived from meta-analysis 
are probably caused by a lower weight given to results 
from studies considered to be of inferior methodological 
quality.
The CVI estimates for erythrocyte related parameters 
were much lower than those derived for leukocyte and 
platelet parameters (Table 2). This is probably caused by 
the longer turnover period of erythrocyte (≈4 months) [28] 
related parameters and that erythrocytes are not “con-
sumed” in the same way as platelets (7–10 days) [29] and 
leukocytes [30]. The lifespan of leukocyte subgroups in 
circulation varies and ranges from days (neutrophils) to 
years (memory cells). Except some subset of lymphocytes 
[31, 32], leukocytes have rapid turnover in the circulation.
For the meta-analysis, we excluded within-day 
studies because the diurnal variation for many constitu-
ents can be high and diurnal variation may be used for 
different purposes than the CVI calculated from studies 
with longer sampling intervals. Despite some exceptions, 
however, based on four studies (papers 28a, 304, 316, 321) 
the within day CVI and CVG were not significantly differ-
ent from daily, weekly or monthly variations provided 
by other studies (Supplementary Table 1). Three studies 
assigned a BIVAC grade A (number 323, 332 and 334) 
reported the CVI and CVG of CBC parameters based on (i) 
weekly samplings for 35 days (medium-term) and (ii) daily 
sampling for 5 days (short-term). The short-term CVI were 
significantly lower than those based on weekly samplings 
for MCV (females), RDW (females), reticulocytes (males) 
and Ret-He (male). Additionally, the short term CVI of 
platelet groups parameters were significantly lower than 
the medium-term CVI, whereas no significant differences 
were observed for the other parameters.
One paper (paper 28) reported a higher CVI estimate 
for basophil based on monthly samplings for 6  months, 
than the papers based on daily or weekly sampling inter-
vals and shorter study periods (Supplementary Table  1). 
However, variations in study design were observed, and 
in order to clarify the effect of different sampling intervals 
and study duration on BV of CBC parameters, standard-
ised studies are warranted.
In the meta-analysis, we only included studies per-
formed in adults between the age of 18 and 75. Despite 
the inclusion of different age groups in various studies, 
the influence of age on BV has not been studied in detail. 
We found that the CIs we derived based on results for Hb 
in paper 325 were extremely high in comparison to those 
found in other studies (Supplementary Figure 2). This may 
be related to the study design or to the included study 
population. Additionally, the CVI estimates of platelets 
derived from one study on subjects aged 80–92 years old 
(paper 246 c,d) were higher than estimates from healthy 
adults. Carobene et  al. assessed the influence of age on 
BV estimates for creatinine, urate, calcium, albumin, total 
cholesterol, high density lipoprotein and low-density 
lipoprotein-cholesterol, triglycerides and iron. Except for 
albumin, they found significantly lower CVI estimates 
in subjects above the age of 78 compared to those below 
36 years [33].
Theoretically, study-related factors such as sex, design 
and pre-analytical handling might affect the derived BV of 
CBC parameters. The mean concentration of erythrocytes 
and Hb in women is lower than men. Although we are 
interested in variation and not the mean level, the men-
strual cycle of women may influence the BV of erythro-
cytes and Hb, but there is no data to support this.
Special attention should be given to CBC parameters 
whose normal levels are close to their limit of quantita-
tion (LOQ), such as basophils and eosinophils. The uncer-
tainty of methods around LOQ is higher than the normal 
concentration. Increasing uncertainty makes methods 
less sensitive and gives a higher CVA which causes wider 
CI of both CVI and CVG. At low concentration particularly 
around LOQ the CVA is higher and therefore it may be 
better to report BV data in SD instead of CV. Although the 
CVI and CVG estimates of both eosinophils and basophils 
obtained from our meta-analysis were lower than the CVI 
and CVG in the HBVD, the estimated BV of these two tests 
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were higher than most of the other CBC parameters prob-
ably due to the low concentration of these cells (Table 2).
Conclusions
A systematic review identified more than 30 papers deliv-
ering BV data for CBC components, but only four of these 
studies were assigned a BIVAC grade A [19–22] and the 
majority a C or D grade. In our study, meta-analysis of 
BIVAC compliant studies (grade A, B and C) has enabled 
publication of updated, global estimates of CVI and CVG 
for CBC parameters. These BV estimates will along with 
estimates for other study populations and other measur-
ands be included in the EFLM Biological Variation Data-
base [23]. The CBC parameters make up a large group of 
heterogeneous tests and with continuous technological 
developments, new parameters will be added. The BV 
data of parameters such as Ret-He and P-LCR are limited 
and new studies should be encouraged to cover these 
parameters. In general, we encourage more high-quality 
studies to be performed for CBC parameters.
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